Abstract
We investigated the virological effectiveness of fluvastatin (an HMG-CoA reductase inhibitor) with 48-week peginterferon (PEG-IFN) and ribavirin combination therapy in patients infected with hepatitis C virus (HCV) genotype 1b and high baseline viral loads. Fluvastatin combination group became HCV-RNA negative significantly earlier during treatment than the matched control group, and SVR rate after 48 weeks combination therapy attained to a high rate, 66.2%. Especially, in females over 50 years old SVR rate attained 40%, we could find that this treatment was beneficial also to elderly females. Although further investigation is necessary, our results suggested that administering fluvastatin with PEG-IFN and ribavirin combination therapy could improve the conventional therapy effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
